Targeting AGE-RAGE signaling pathway by Saxagliptin prevents myocardial injury in isoproterenol challenged diabetic rats.
Rajiv KumarPoorva BhargavaKapiil SuchalJagriti BhatiaDharamvir Singh AryaPublished in: Drug development research (2021)
The role of Saxagliptin in diabetes-associated cardiovascular complications is controversial. This study aimed to investigate whether Saxagliptin could prevent Isoproterenol-induced myocardial changes in diabetic rats and to identify the possible mechanism as well. The high-fat diet/low-dose Streptozotocin-induced type 2 diabetic rats were divided into 3 groups: the control group (0.25% CMC for 28 days), the Isoproterenol group (85 mg/kg Isoproterenol for the last 2 days plus 0.25% CMC for 28 days), and the treatment group (10 mg/kg Saxagliptin for 28 days plus 85 mg/kg Isoproterenol for the last 2 days). Hemodynamic measurements were performed, and samples were examined for RAGE and NF-κB expressions, histopathological and ultrastructural changes, AGEs level, myocardial injury markers, oxidative stress, and apoptosis. Saxagliptin significantly recovered cardiac function (p < .001), reverted myocardial injury and oxidative stress levels back to the control value (p < .05 to p < .001). Saxagliptin alleviates Isoproterenol-induced myocardial injury in diabetic rats by suppressing AGE-RAGE pathway.
Keyphrases
- diabetic rats
- oxidative stress
- high fat diet
- signaling pathway
- low dose
- induced apoptosis
- dna damage
- ischemia reperfusion injury
- type diabetes
- adipose tissue
- left ventricular
- metabolic syndrome
- cell death
- high dose
- risk factors
- inflammatory response
- drug delivery
- immune response
- atrial fibrillation
- lps induced
- toll like receptor
- cell cycle arrest